🔎 Trials Near Me

Utama › Kanser Payudara Triple-Negatif › New Jersey › Edison

Kajian klinikal Kanser Payudara Triple-Negatif di Edison, NJ

11 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar Edison (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • START New Jersey, East Brunswick · 6 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Mengambil peserta
  • Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees, Voorhees Township · 5 mi jauh
Umur 30 ke atas · Wanita · Dikemas kini 25 Sep 2026 · NCT02945579

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Mengambil pesertaFasa 3
  • Rutgers Cancer Institute of New Jersey ( Site 0076), New Brunswick · 3 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Mengambil pesertaFasa 1
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06246968

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Mengambil pesertaFasa 2
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge · 15 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05570253

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Mengambil pesertaFasa 3
  • Rutgers Health, New Brunswick · 3 mi jauh
  • Regional Cancer Care Associates LLC, East Brunswick · 6 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05633654

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

Mengambil pesertaFasa 2
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauh
Umur 70 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07768436

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Mengambil pesertaFasa 2
  • Rutgers Cancer Institute of New Jersey, New Brunswick · 3 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT01042379

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Mengambil pesertaFasa 2
  • Memorial Sloan Kettering Basking Ridge, Basking Ridge · 15 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Feb 2026 · NCT03808337

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Mengambil pesertaFasa 2
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi jauh
Umur 18 ke atas · Wanita · Dikemas kini 17 Feb 2026 · NCT04683679

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Mengambil pesertaFasa 2
  • Rutgers Cancer Institute of New Jersey, New Brunswick · 3 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Jun 2025 · NCT06568692

Kajian Kanser Payudara Triple-Negatif di bandar lain

Kajian lain di Edison

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.